Anti-inflammatory and Anti-arthritic Effects of a Novel Leflunomide Analogue, UTL-5b (GBL-5b).
Rheumatoid arthritis (RA) is a common disease characterized by chronic inflammation and irreversible destruction of articular cartilage and bone. In this report, we examined the anti-inflammatory and anti-arthritic effects of a novel leflunomide analogue, UTL-5b (also known as GBL-5b), for potential RA treatment. Using a carrageenan-induced edema study in rats, UTL-5b exhibited a better anti-inflammatory effect as compared with leflunomide and its metabolite. The chronic efficacy of UTL-5b was examined using type II collagen-induced arthritis (CIA) mouse model. UTL-5b exerted an anti-arthritic effect in a dose-dependant manner with mice given 30 mg/kg exhibiting amelioration of disease early in the trial, but losing statistical significance over time. In contrast, mice treated with 60 mg/kg showed reduced clinical disease parameters early in the trial and these effects were sustained over the ten week trial period. Mechanistic studies indicate that UTL-5b is an inhibitor of TNF-α production in vivo. Oral administration of UTL-5b prior to i.p. injection with lethal dose of lipopolysaccharide (LPS)/D-galactosamine markedly reduced the levels of serum TNF-α and increased survival rates of animals from septic shock-induced death. Acute toxicity study using mice receiving increasing doses of UTL-5b showed that no animals were killed by UTL-5b at 2,000 mg/kg (LD(50) >2,000 mg/kg). Our studies show that UTL-5b represents a novel anti-inflammatory and anti-arthritic agent with potential therapeutic application for RA treatment.
Unitech Pharmaceuticals, Inc., Ann Arbor, MI 48108, USA.
Jiajiu
J
Shaw
Ben
B
Chen
Paul
P
Wooley
Wen-Hsin
WH
Huang
An-Rong
AR
Lee
Dustin
D
Zeng
Clin Ther. 1999 Nov;21(11):1837-52; discussion 1821
10890256
Mini Rev Med Chem. 2010 Feb;10(2):98-107
20432529
Biochemistry. 1996 Jan 30;35(4):1270-3
8573583
Immunology. 1996 Dec;89(4):553-7
9014820
Br J Pharmacol. 1999 Sep;128(1):5-12
10498828
Ann Rheum Dis. 2003 Apr;62(4):297-302
12634225
Ann Rheum Dis. 2000 Nov;59(11):841-9
11053058
J Exp Med. 1981 Sep 1;154(3):688-700
6792316
J Rheumatol. 2003 Jun;30(6):1182-90
12784387
Orthop Nurs. 2003 Jan-Feb;22(1):48-51
12640952
Annu Rev Med. 2000;51:207-29
10774461
Am J Med Sci. 2002 Apr;323(4):190-3
12003373
Clin Immunol. 2002 Jun;103(3 Pt 1):231-42
12173297
J Pharmacol Exp Ther. 1995 Nov;275(2):1043-9
7473131
World J Gastroenterol. 2003 Feb;9(2):320-3
12532458
Chem Pharm Bull (Tokyo). 2003 Mar;51(3):313-4
12612418
J Clin Invest. 1990 Dec;86(6):1790-8
2174906
Curr Opin Investig Drugs. 2001 Feb;2(2):222-30
11816835
Curr Opin Rheumatol. 2002 May;14(3):204-11
11981314
Lancet. 2007 Dec 1;370(9602):1861-74
17570481
Proc Soc Exp Biol Med. 1962 Dec;111:544-7
14001233
Curr Opin Rheumatol. 2001 May;13(3):193-201
11333348